

Nivo/Ipi (nivolumab and ipilimumab) CheckMate 648

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



### Serious and disabling adverse effects



### Other adjustments



Nivo/Ipi (nivolumab and ipilimumab) CheckMate 648

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression  $\geq 1\%$

Experimental Arm: Nivo/Ipi (nivolumab and ipilimumab)

Control Arm: ChT



